Evidence map›Paper›PMID 18160514›Full record

ArticleAntimicrobial agents and chemotherapy2008

Enhanced production of phospholipase C and perfringolysin O (alpha and theta toxins) in a gatifloxacin-resistant strain of Clostridium perfringens.

Fatemeh Rafii, Miseon Park, Amy E Bryant, Shemedia J Johnson, Robert D Wagner

Abstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Fatemeh RafiiDivision of Microbiology, National Center for Toxicological Research, 3900 NCTR Dr., Jefferson, AR 72079, USA. Fatemeh.Rafii@fda.hhs.gov
Miseon Park
Amy E Bryant
Shemedia J Johnson
Robert D Wagner
National Center for Toxicological Research · USBoise VA Medical Center · US

Funding

TRANSCRIPTIONAL ATTENUATION OF THE TYPE I INTERFERON RESPONSE BY RHINOVIRUSP20RR015587 · NCRR · UNIVERSITY OF IDAHO · PI BOHACH, GREGORY A · 2000 to 2009
$19.0M
NCRR NIH HHS P20 RR015587NCRR NIH HHS P20RR15587
6 · The paper itself

Abstract

Clostridium perfringens-induced gas gangrene is mediated by potent extracellular toxins, especially alpha toxin (a phospholipase C [PLC]) and theta toxin (perfringolysin O [PFO], a thiol-activated cytolysin); and antibiotic-induced suppression of toxin synthesis is an important clinical goal. The production of PLC and PFO by a gatifloxacin-induced, fluoroquinolone-resistant mutant strain of C. perfringens, strain 10G, carrying a stable mutation in DNA gyrase was compared with that of the wild-type (WT) parent strain. Zymography (with sheep red blood cell and egg yolk overlays) and time course analysis [with hydrolysis of egg yolk lecithin and O-(4 nitrophenyl-phosphoryl)choline] demonstrated that strain 10G produced more PLC and PFO than the WT strain. Increased toxin production in strain 10G was not related either to differences in growth characteristics between the wild-type and the mutant strain or to nonsynonymous polymorphisms in PLC, PFO, or their known regulatory proteins. Increased PLC and PFO production by strain 10G was associated with increased cytotoxic activity for HT-29 human adenocarcinoma cells and with increased platelet-neutrophil aggregate formation. Four other gatifloxacin-induced gyrase mutants did not show increased toxin production, suggesting that gatifloxacin resistance was not always associated with increased toxin production in all strains of C. perfringens. This is the first report of increased toxin production in a fluoroquinolone-resistant strain of C. perfringens.

Indexed as

Anti-Bacterial AgentsBacterial ToxinsCell Line, TumorClostridium perfringensDrug Resistance, BacterialFluoroquinolonesGatifloxacinHemolysin ProteinsHumansMutationType C PhospholipasesUp-RegulationAnti-Bacterial AgentsBacterial ToxinsClostridium perfringens theta-toxinFluoroquinolonesGatifloxacinHemolysin ProteinsType C Phospholipases

Identifiers

PMID18160514
PMCPMC2258526
OpenAlexW2121258455

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.